136 related articles for article (PubMed ID: 28782122)
1. Nevirapine patch testing in Thai human immunodeficiency virus infected patients with nevirapine drug hypersensitivity.
Prasertvit P; Chareonyingwattana A; Wattanakrai P
Contact Dermatitis; 2017 Dec; 77(6):379-384. PubMed ID: 28782122
[TBL] [Abstract][Full Text] [Related]
2. Use of patch testing for the diagnosis of abacavir-related hypersensitivity reaction in HIV patients.
Giorgini S; Martinelli C; Tognetti L; Carocci A; Giuntini R; Mastronardi V; Torricelli F; Leoncini F; Lotti T
Dermatol Ther; 2011; 24(6):591-4. PubMed ID: 22515676
[TBL] [Abstract][Full Text] [Related]
3. HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients.
Chantarangsu S; Mushiroda T; Mahasirimongkol S; Kiertiburanakul S; Sungkanuparph S; Manosuthi W; Tantisiriwat W; Charoenyingwattana A; Sura T; Chantratita W; Nakamura Y
Pharmacogenet Genomics; 2009 Feb; 19(2):139-46. PubMed ID: 19104471
[TBL] [Abstract][Full Text] [Related]
4. Prednisolone does not prevent hypersensitivity reactions in antiretroviral drug regimens containing abacavir with or without nevirapine.
Wit FW; Wood R; Horban A; Beniowski M; Schmidt RE; Gray G; Lazzarin A; Lafeuillade A; Paes D; Carlier H; van Weert L; de Vries C; van Leeuwen R; Lange JM
AIDS; 2001 Dec; 15(18):2423-9. PubMed ID: 11740193
[TBL] [Abstract][Full Text] [Related]
5. HLA-dependent hypersensitivity reaction to nevirapine in Chinese Han HIV-infected patients.
Gao S; Gui XE; Liang K; Liu Z; Hu J; Dong B
AIDS Res Hum Retroviruses; 2012 Jun; 28(6):540-3. PubMed ID: 21902584
[TBL] [Abstract][Full Text] [Related]
6. Twenty-four-week efficacy and safety of switching virologically suppressed HIV-1-infected patients from nevirapine immediate release 200 mg twice daily to nevirapine extended release 400 mg once daily (TRANxITION).
Arasteh K; Ward D; Plettenberg A; Livrozet JM; Orkin C; Cordes C; Guo J; Wang E; Yong CL; Robinson P; Quinson A
HIV Med; 2012 Apr; 13(4):236-44. PubMed ID: 22136068
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of nevirapine- versus efavirenz-containing regimens in HIV-infected Thai children.
Lapphra K; Vanprapar N; Chearskul S; Phongsamart W; Chearskul P; Prasitsuebsai W; Chokephaibulkit K
Int J Infect Dis; 2008 Nov; 12(6):e33-8. PubMed ID: 18573672
[TBL] [Abstract][Full Text] [Related]
8. HLA-B*5701 screening for hypersensitivity to abacavir.
Mallal S; Phillips E; Carosi G; Molina JM; Workman C; Tomazic J; Jägel-Guedes E; Rugina S; Kozyrev O; Cid JF; Hay P; Nolan D; Hughes S; Hughes A; Ryan S; Fitch N; Thorborn D; Benbow A;
N Engl J Med; 2008 Feb; 358(6):568-79. PubMed ID: 18256392
[TBL] [Abstract][Full Text] [Related]
9. Refining abacavir hypersensitivity diagnoses using a structured clinical assessment and genetic testing in the Swiss HIV Cohort Study.
Rauch A; Nolan D; Thurnheer C; Fux CA; Cavassini M; Chave JP; Opravil M; Phillips E; Mallal S; Furrer H;
Antivir Ther; 2008; 13(8):1019-28. PubMed ID: 19195327
[TBL] [Abstract][Full Text] [Related]
10. Shared peptide binding of HLA Class I and II alleles associate with cutaneous nevirapine hypersensitivity and identify novel risk alleles.
Pavlos R; McKinnon EJ; Ostrov DA; Peters B; Buus S; Koelle D; Chopra A; Schutte R; Rive C; Redwood A; Restrepo S; Bracey A; Kaever T; Myers P; Speers E; Malaker SA; Shabanowitz J; Jing Y; Gaudieri S; Hunt DF; Carrington M; Haas DW; Mallal S; Phillips EJ
Sci Rep; 2017 Aug; 7(1):8653. PubMed ID: 28819312
[TBL] [Abstract][Full Text] [Related]
11. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
Lucas A; Nolan D; Mallal S
J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
[TBL] [Abstract][Full Text] [Related]
12. Associations between human leukocyte antigen polymorphisms and hypersensitivity to antiretroviral therapy in patients with human immunodeficiency virus: a meta-analysis.
Hu K; Xiang Q; Wang Z; Mu GY; Zhang Z; Ma LY; Xie QF; Chen SQ; Zhou S; Zhang XD; Cui YM
BMC Infect Dis; 2019 Jul; 19(1):583. PubMed ID: 31277607
[TBL] [Abstract][Full Text] [Related]
13. Prevalence of HLA-B*57:01 allele in Argentinean HIV-1 infected patients.
Moragas M; Belloso WH; Baquedano MS; Gutierrez MI; Bissio E; Larriba JM; Fay F; Aulicino P; Gurevich JM; Yaunguzian MF; Maldonado AC; Falistocco C; Sen L; Mangano A
Tissue Antigens; 2015 Jul; 86(1):28-31. PubMed ID: 25922880
[TBL] [Abstract][Full Text] [Related]
14. Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population.
Carr DF; Chaponda M; Jorgensen AL; Castro EC; van Oosterhout JJ; Khoo SH; Lalloo DG; Heyderman RS; Alfirevic A; Pirmohamed M
Clin Infect Dis; 2013 May; 56(9):1330-9. PubMed ID: 23362284
[TBL] [Abstract][Full Text] [Related]
15. Association of Human Leukocyte Antigen Alleles and Hypersensitivity of Efavirenz/Nevirapine in HIV-Infected Chinese Patients.
Zhou XY; Li CX; Zhang JB; Tan JT; -Yang X; Albarmaqi RA; Li YY; Kuang YQ
AIDS Res Hum Retroviruses; 2022 Dec; 38(12):884-889. PubMed ID: 36226442
[TBL] [Abstract][Full Text] [Related]
16. A simple screening approach to reduce B*5701-associated abacavir hypersensitivity on the basis of sequence variation in HIV reverse transcriptase.
Chui CK; Brumme ZL; Brumme CJ; Yip B; Phillips EJ; Montaner JS; Harrigan PR
Clin Infect Dis; 2007 Jun; 44(11):1503-8. PubMed ID: 17479950
[TBL] [Abstract][Full Text] [Related]
17. Value of the HLA-B*5701 allele to predict abacavir hypersensitivity in Spaniards.
Rodríguez-Nóvoa S; García-Gascó P; Blanco F; González-Pardo G; Castellares C; Moreno V; Jiménez-Nácher I; González-Lahoz J; Soriano V
AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1374-6. PubMed ID: 18184080
[TBL] [Abstract][Full Text] [Related]
18. HLA Class I restricted CD8+ and Class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity.
Keane NM; Pavlos RK; McKinnon E; Lucas A; Rive C; Blyth CC; Dunn D; Lucas M; Mallal S; Phillips E
AIDS; 2014 Aug; 28(13):1891-901. PubMed ID: 24911354
[TBL] [Abstract][Full Text] [Related]
19. A review of drug patch testing and implications for HIV clinicians.
Shear NH; Milpied B; Bruynzeel DP; Phillips EJ
AIDS; 2008 May; 22(9):999-1007. PubMed ID: 18520343
[No Abstract] [Full Text] [Related]
20. Safety and efficacy of once-daily nevirapine dosing: a multicohort study.
Calmy A; Vallier N; Nguyen A; Lange JM; Battegay M; de Wolf F; Reiss P; Lima VD; Hirschel B; Hogg RS; Yip B; Montaner JS; Wit FW; ; ;
Antivir Ther; 2009; 14(7):931-8. PubMed ID: 19918097
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
